AUDI AG:企業の戦略・SWOT・財務情報

◆英語タイトル:AUDI AG - Strategy, SWOT and Corporate Finance Report
◆商品コード:DATA904C5583
◆発行会社(調査会社):MarketLine
◆発行日:2018年10月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:自動車
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD175 ⇒換算¥25,900見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD350 ⇒換算¥51,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD525 ⇒換算¥77,700見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketLine社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
MarketLine社の概要はこちらでご確認いただけます。



【レポートの概要】

AUDI AG – Strategy, SWOT and Corporate Finance Report
Summary

AUDI AG – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

AUDI AG (Audi or ‘the company’) is engaged in the development, production, assembly and distribution of vehicles, including cars and motorcycles. The company is active both in the premium and supercar segments through its brands Audi, Lamborghini, and Ducati. It is headquartered in Ingolstadt, Germany.

Scope

- Detailed information on AUDI AG required for business and competitor intelligence needs
- A study of the major internal and external factors affecting AUDI AG in the form of a SWOT analysis
- An in-depth view of the business model of AUDI AG including a breakdown and examination of key business segments
- Intelligence on AUDI AG’s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about AUDI AG, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of AUDI AG and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess AUDI AG as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers’ businesses better.
- Stay up to date on AUDI AG’s business structure, strategy and prospects.

【レポートの目次】

Table of Contents
Company Snapshot 2
Table of Contents 5
AUDI AG: Company Overview 9
AUDI AG: Overview and Key Facts 9
AUDI AG: Overview 9
AUDI AG: Key Facts 9
AUDI AG: Key Employees 10
AUDI AG: Key Employee Biographies 12
AUDI AG: Major Products and Services 19
AUDI AG: Company History 20
AUDI AG: Management Statement 25
AUDI AG: Locations and Subsidiaries 26
AUDI AG: Key Competitors 27
AUDI AG: Company Analysis 28
AUDI AG: Business Description 28
AUDI AG: SWOT Analysis 30
AUDI AG: SWOT Overview 30
AUDI AG: Strengths 30
AUDI AG: Weaknesses 31
AUDI AG: Opportunities 32
AUDI AG: Threats 33
AUDI AG: Corporate Financial Deals Activity 35
AUDI AG: Financial Deals Overview 35
AUDI AG: Targets and Partners 37
AUDI AG: Top Deals 2014 – 2018YTD* 38
AUDI AG: Mergers and Acquisitions 39
AUDI AG: Corporate Venturing 40
AUDI AG: Partnership 41
AUDI AG: Divestments 42
AUDI AG: Recent Developments 43
AUDI AG: News and Events Summary 43
AUDI AG: Business Expansion 46
AUDI AG: Contracts 46
AUDI AG: Financial Deals 47
AUDI AG: Market Developments 48
AUDI AG: Regulatory and Legal Events 48
AUDI AG: Strategy and Operations 49
Appendix 50
Contact Us 50
Methodology 50
About MarketLine 51

List of Tables
Table 1: AUDI AG: Key Facts
Table 2: AUDI AG: Key Employees
Table 3: AUDI AG: Company History
Table 4: AUDI AG: Locations and Subsidiaries
Table 5: AUDI AG: Key Competitors
Table 6: AUDI AG: Deal Activity by Deal Type - Volume (TTM*)
Table 7: AUDI AG: Deal Activity by Deal Type - Volume (2014 - YTD*2018)
Table 8: AUDI AG: M&A Average Deal Size - Value (US$m)
Table 9: AUDI AG: Targets and Partners
Table 10: AUDI AG: Top Deals 2014 - 2018YTD*
Table 11: AUDI AG: M&A Volume and Value Trend (2014 - YTD*2018)
Table 12: AUDI AG: M&A Activity by Geography (2014 - YTD*2018)
Table 13: AUDI AG: Corporate Venturing Volume and Value Trend (2014 - YTD*2018)
Table 14: AUDI AG: Corporate Venturing by Geography (2014 - YTD*2018)
Table 15: AUDI AG: Partnership Volume and Value Trend (2014 - YTD*2018)
Table 16: AUDI AG: Partnership Trend by Deal Type (2014 - YTD*2018)
Table 17: AUDI AG: Divestments Volume and Value Trend (2014 - YTD*2018)
Table 18: AUDI AG: News and Events Summary
Table 19: AUDI AG: Business Expansion
Table 20: AUDI AG: Contracts
Table 21: AUDI AG: Financial Deals
Table 22: AUDI AG: Market Developments
Table 23: AUDI AG: Regulatory and Legal Events
Table 24: AUDI AG: Strategy and Operations

List of Figures
Figure 1: AUDI AG: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: AUDI AG: Deal Activity by Deal Type - Volume (2014 - YTD*2018)
Figure 3: AUDI AG: M&A Average Deal Size - Value (US$m)
Figure 4: AUDI AG: M&A Volume and Value Trend (2014 - YTD*2018)
Figure 5: AUDI AG: M&A Activity by Geography (2014 - YTD*2018)
Figure 6: AUDI AG: Corporate Venturing Volume and Value Trend (2014 - YTD*2018)
Figure 7: AUDI AG: Corporate Venturing by Geography (2014 - YTD*2018)
Figure 8: AUDI AG: Partnership Volume and Value Trend (2014 - YTD*2018)
Figure 9: AUDI AG: Partnership Trend by Deal Type (2014 - YTD*2018)
Figure 10: AUDI AG: Divestments Volume and Value Trend (2014 - YTD*2018)

★海外企業調査レポート[AUDI AG:企業の戦略・SWOT・財務情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Novartis AG (NOVN):企業の財務・戦略的SWOT分析
    Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Lunaphore Technologies SA:医療機器:M&Aディール及び事業提携情報
    Summary Lunaphore Technologies SA (Lunaphore) is a medical device company that develops tissue processing solutions for inmmunohistochemistry. The company builds tumor analysis and classification platforms based on a microfluidic technologies. It offers FFeX, a fast fluidic exchange technology that …
  • Sawai Pharmaceutical Co Ltd (4555):製薬・医療:M&Aディール及び事業提携情報
    Summary Sawai Pharmaceutical Co Ltd (Sawai Pharmaceutical) manufactures, sells, imports and exports ethical drugs and proprietary drugs. The company's products include cardiovascular drugs, antihyperlipidemic agents, diabetes drugs, anticancer drugs, and OTC drugs. It provides products in the form o …
  • Alten SA:企業の戦略・SWOT・財務情報
    Alten SA - Strategy, SWOT and Corporate Finance Report Summary Alten SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Southern California Gas Co:企業の戦略的SWOT分析
    Southern California Gas Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Guardant Health Inc (GH):企業の製品パイプライン分析2018
    Summary Guardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics company that commercializes genomic liquid biopsy. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection …
  • Intrusion Inc (INTZ):企業の財務・戦略的SWOT分析
    Summary Intrusion Inc (Intrusion) is a technology company. The company offers network monitoring and analysis solutions. Its product portfolio includes Savant, TraceCop that enables identification of malicious and illegal activities, Secure Tap a suite of network tap products that enables deployment …
  • iDD biotech SAS-製薬・医療分野:企業M&A・提携分析
    Summary iDD biotech SAS (iDD biotech) is a healthcare products provider that discovers and develops differentiated therapeutic antibodies. The company's products comprise pre-clinical stage therapeutic monoclonal antibodies and active drug discovery programs. It develops therapies for the treatment …
  • CardioComm Solutions Inc (EKG):企業の製品パイプライン分析
    Summary CardioComm Solutions Inc (CardioComm) is a medical technology company that offers software solutions for information management systems in cardiovascular medicine and telemedicine. It offers software engineering of computer based electrocardiogram management and reporting software. Its produ …
  • SynCore Biotechnology Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary SynCore Biotechnology Co Ltd (SynCore), a subsidiary of Sinphar Pharmaceutical Co Ltd is a biopharmaceutial company that utilizes and in-licenses technologies to develop new drugs. The company’s pipeline products include SB01, SB02, SB03, SB04 and SB05. Its SB01 drug is a new chemical entity …
  • Mississippi Power Co:企業の戦略的SWOT分析
    Mississippi Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Eutelsat Communications Group:企業の戦略・SWOT・財務分析
    Eutelsat Communications Group - Strategy, SWOT and Corporate Finance Report Summary Eutelsat Communications Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Lotus Bakeries NV:企業の戦略・SWOT・財務情報
    Lotus Bakeries NV - Strategy, SWOT and Corporate Finance Report Summary Lotus Bakeries NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Gr. Sarantis S.A. (SAR):企業の財務・戦略的SWOT分析
    Gr. Sarantis S.A. (SAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Trammo Inc:企業の戦略的SWOT分析
    Trammo Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Royal Mail Plc (RMG):企業の財務・戦略的SWOT分析
    Royal Mail Plc (RMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Neurocrine Biosciences Inc (NBIX):製薬・医療:M&Aディール及び事業提携情報
    Summary Neurocrine Biosciences Inc (Neurocrine) discovers, develops and commercializes pharmaceutical products for the treatment of neurologic, psychiatric and endocrine related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule is a US FDA approved selective vesicular monoamin …
  • Dixons Carphone plc:企業のM&A・事業提携・投資動向
    Dixons Carphone plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dixons Carphone plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Incanthera Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Incanthera Ltd (Incanthera) is a drug development and targeted cancer medicines company that discovers and develops novel treatments for solid tumours. The company's pipeline drug candidates include ICT01-2588, a vascular disrupting agent, based on the tumor-blasting technology; ICT03 – Es5, …
  • Chiesi USA Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Chiesi USA Inc (Chiesi USA), a subsidiary of Chiesi Farmaceutici S.p.A, is a specialty pharmaceutical company. It researches, develops, produces and commercializes therapies in cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. The company's product portfol …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆